Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an allergy drug shield diabetics from organ damage?

NCT ID NCT07685886

Not yet recruiting Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether montelukast, a common allergy medication, can reduce damage to the kidneys, eyes, and blood vessels in adults with type 2 diabetes and early kidney disease. The drug works by blocking inflammatory chemicals called leukotrienes, which are linked to diabetes complications. Participants take either montelukast or a placebo daily for 12 months while researchers measure changes in kidney function, blood vessel health, and eye health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
montelukast
What this could lead to
If it works, montelukast could become a new, affordable way to slow or prevent kidney, eye, and blood vessel damage in people with type 2 diabetes.
What could go wrong
This is a small, early-phase trial, so results may not apply to everyone. Montelukast is generally safe but may cause side effects like headache or digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic kidney disease impaired renal function disease kidney disorder retinal disorder type 2 diabetes mellitus vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES KIDNEY DISEASE RETINOPATHY VASCULAR DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Colorado Denver

    Aurora, Colorado, 80045, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.